FDA Approves Gene Therapy Itvisma for Spinal Muscular Atrophy Treatment
The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve), a gene therapy treatment for spinal muscular atrophy in patients 2 years and older with confirmed SMN1 gene mutations. The approval marks a significant advancement in treating this rare genetic condition that affects muscle strength and movement.